-
Dasatinib, sold
under the
brand name
Sprycel among others, is a
targeted therapy medication used to
treat certain cases of
chronic myelogenous leukemia...
- to TK inhibitors, four
novel agents were
later developed. The first,
dasatinib,
blocks several further oncogenic proteins, in
addition to more potent...
-
except for T315I.
Dasatinib is also not a
substrate of
multidrug P-glycoprotein
efflux pumps like imatinib.
Because of this
dasatinib may be
active in...
- sofosbuvir, afatinib, axitinib, brigatinib, baricitinib, cabozantinib,
dasatinib, neratinib, eltrombopag, ibrutinib, lenvatinib, palbociclib, regorafenib...
- are point-mutations in the
kinase of BCR-abl. New
inhibitors include dasatinib and nilotinib,
which are
significantly more
potent than
imatinib and may...
- symptoms.
Among currently available inhibitors to
treat CML are imatinib,
dasatinib, nilotinib,
bosutinib and ponatinib.
Gastrointestinal stromal tumors (GIST)...
- are
repurposed anti-cancer molecules, such as the
chemotherapeutic drug
dasatinib and the
experimental small molecule navitoclax.
Soluble urokinase plasminogen...
- 2006: FDA
Approval of
Dasatinib and
Nilotinib for
Resistant Leukemia MD
Anderson researchers demonstrate the
efficacy of
dasatinib and nilotinib, leading...
-
leukemia (CML) and
later gefitinib and
erlotinib aiming at the EGF receptor.
Dasatinib is a Src
tyrosine kinase inhibitor that is
effective both as a senolytic...
- alefacept, and the
tyrosine kinase inhibitors, imatinib, nilotinib, and
dasatinib.
Experimental therapies under investigation include endothelin receptor...
